AWM
JAZZ icon

Affinity Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Affinity Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$481K Sell
1,995
-632
-24% -$138K 0.06% 63
2026
Q1 		$497K Hold
2,627
– – 0.08% 58
2025
Q4 		$447K Hold
2,627
– – 0.06% 63
2025
Q3 		$346K Hold
2,627
– – 0.05% 72
2025
Q2 		$279K Buy
+2,627
New +$285K 0.04% 85

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Affinity Wealth Management's JAZZ Position: Q2 2026 in Review

Affinity Wealth Management reduced its Jazz Pharmaceuticals (JAZZ) stake by 24% in Q2 2026, selling an estimated $138K and leaving 1,995 shares worth $481K. The position accounts for 0.06% of the portfolio, ranked #63.

Affinity Wealth Management first reported a position in JAZZ in Q2 2025 and has held it in 5 quarters since. The position peaked at $497K in Q1 2026. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Affinity Wealth Management held 1,995 shares of Jazz Pharmaceuticals worth $481K as of Q2 2026.
  • Affinity Wealth Management sold 632 Jazz Pharmaceuticals shares in Q2 2026, an estimated $138K.
  • Jazz Pharmaceuticals made up 0.06% of Affinity Wealth Management's portfolio in Q2 2026, its #63 holding.
  • Affinity Wealth Management first reported a position in Jazz Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Affinity Wealth Management's Jazz Pharmaceuticals position peaked at $497K in Q1 2026.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Affinity Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.